Institutional members access full text with Ovid®

Allergy immunotherapy: what is the evidence for cost saving?

Hankin, Cheryl S.; Cox, Linda

Current Opinion in Allergy & Clinical Immunology: August 2014 - Volume 14 - Issue 4 - p 363–370
doi: 10.1097/ACI.0000000000000084
PHARMACOTHERAPY AND EVIDENCE BASED MEDICINE: Edited by David A. Khan and Enrico Compalati
Editor's Choice

Purpose of review: Given the widespread prevalence of allergic disease, its substantially associated clinical and economic burden, the unique disease-modifying benefits of allergy immunotherapy (AIT), and increased availability of sublingual immunotherapy (SLIT), a critical update of the evidence for AIT-related cost savings [for both subcutaneous immunotherapy (SCIT) and SLIT] is particularly relevant and timely. The present article reviews the evidence for SCIT-related and SLIT-related cost savings derived from a systematic review of the published literature.

Recent findings: Examined were 24 publications pertaining to the health economics of AIT. Except for one early study comparing the costs of AIT to symptomatic drug treatment (SDT), the remainder provide compelling evidence for AIT cost savings (whether SCIT or SLIT) over SDT. Furthermore, of the six studies comparing cost outcomes of SLIT to SCIT, four reported cost savings favoring SLIT.

Summary: This review, spanning research from Southern Europe, Scandinavia, Northern Europe, North America, and the Czech Republic, encompasses a range of perennial and seasonal allergic conditions, including allergic asthma, allergic rhinitis with or without asthma, and rhinoconjunctivitis with or without allergic rhinitis due to house dust mite, grass or ragweed pollen, or a mixture of various allergens. All but one study compellingly demonstrate cost savings conferred by AIT over SDT.

aBioMedEcon, Moss Beach, California

bAllergy and Asthma Center, Fort Lauderdale, Florida, USA

Correspondence to Cheryl Hankin, PhD, PO Box 129, Moss Beach, CA 94038, USA. Tel: +1 650 563 9475; fax: +1 650 563 9485; e-mail: chankin@biomedecon.com

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (www.co-allergy.com).

Copyright © 2014 Wolters Kluwer Health, Inc. All rights reserved.